Navigation Links
Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations
Date:9/10/2007
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 2Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 3Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 4Heska Announces Extension of Credit Agreement With Wells Fargo 2Heska Announces Extension of Credit Agreement With Wells Fargo 3Jennifer Dodson M D named 2009 AUA Foundation NIDDK NCI Surgeon Scientist Award winner 49928 1NYU Langone Medical Center awarded NIH grants totaling 241 560 000 8981 1NYU Langone Medical Center awarded NIH grants totaling 241 560 000 8981 2NYU Langone Medical Center awarded NIH grants totaling 241 560 000 8981 3Perrigo Confirms That its Partner Synthon Has Filed for Generic Version of Xyzal 28R 29 Solution and Announcement of Lawsuit by Sepracor UCB 49926 1Perrigo Confirms That its Partner Synthon Has Filed for Generic Version of Xyzal 28R 29 Solution and Announcement of Lawsuit by Sepracor UCB 49926 2Perrigo Confirms That its Partner Synthon Has Filed for Generic Version of Xyzal 28R 29 Solution and Announcement of Lawsuit by Sepracor UCB 49926 3